Dave Levitan

The Short-HER study was unable to show noninferiority of 9 weeks of trastuzumab compared with the standard 1 year in women with HER2-positive breast cancer.

A study shows that combined hormonal contraceptive use is associated with a significant reduction in the risk of ovarian cancer.

Nearly 10 years of follow-up from a large clinical trial have confirmed that axillary dissection is not necessary in patients with early breast cancer.

The combination of encorafenib and binimetinib resulted in longer overall survival compared with vemurafenib in patients with BRAF V600–mutant melanoma.

New research suggests that immune resistance in urothelial cancer may be mediated by stromal cells, which act as a source of EMT-related gene expression.

A new proteomic analysis found that CT45 is an independent prognostic factor in patients with high-grade serous ovarian cancer, and a potential target of immunotherapies.

For patients with NETs that have metastasized to the liver, high levels of serum pancreastatin are predictive of poor outcomes after treatment with TACE.

A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.

Survival has increased substantially for young women with breast cancer since 1975, though it has largely reached a plateau since around 2005.

A new study suggests that the cytokine CXCL12 could be useful as a prognostic biomarker in patients with neuroendocrine tumors of the lung.

A new laboratory study has shed some light on how mitochondrial metabolism is altered in breast cancer.

Outcomes for patients with HER2-positive breast cancer did not differ when treated with sequential chemotherapy plus trastuzumab compared with a concurrent approach.

The combination of pembrolizumab and a TLR9 agonist known as SD-101 showed promising activity in patients with unresectable or metastatic melanoma.

A 17-gene signature derived from circulating tumor cells was found to correlate with response to therapy in patients with breast cancer.

Active surveillance could help lead to early excision of melanoma, and thus better outcomes, in patients with CLL.

Treatment with talazoparib improved quality of life vs physician’s choice of chemotherapy in patients with HER2-negative advanced breast cancer.

A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important.

Sorafenib combined with topotecan and then continued as maintenance therapy offered a significant improvement in survival outcomes in women with platinum-resistant ovarian cancer.

Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma.

Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.

Baseline levels of lactate dehydrogenase are significantly associated with progression-free survival outcomes in patients with BRAF V600–mutated metastatic melanoma.

A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.

A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.

The presence of HER3 expression and a high HER2/CEP17 ratio distinguish a group of invasive HER2-positive ductal breast cancer patients who have a worse prognosis.

Low-dose CT screening for lung cancer is recommended for certain individuals, but two new studies highlight some of the limitations and growing pains of a screening program.

An existing body of literature shows that marital status and related social support are connected with disease outcomes.

A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.

Internal mammary chain radiation therapy for breast cancer is associated with increased cardiac toxicity, in particular when paired with anthracyclines.

Many breast cancer patients report that clinicians do not engage adequately regarding management of financial toxicity associated with their diagnosis, according to a new survey.

The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer.